Clinical Trial Update: Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tislelizumab as a single-agent neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Esophagus Cancer | Phase 2 | Status: NOT_YET_RECRUITING